Lupus & antiphospholipid syndrome
Development of American College of Rheumatology Quality Measures for Systemic Lupus Erythematosus: A Modified Delphi Process With Rheumatology Informatics System for Effectiveness (RISE) Registry Data Review
Authors' conclusion
The Delphi process selected 3 quality measures for SLE care on hydroxychloroquine, glucocorticoid reduction, and kidney monitoring.
Study context
- Population
- North American and European guidelines from 2000 to 2020 on treatment, monitoring and phenotyping of systemic lupus erythematosus (SLE), reviewed by an American College of Rheumatology (ACR) workgroup of SLE experts
- Outcome
- SLE digital quality measure statements
Methodological detailsmodified Delphi process, 3 consecutive Delphi sessions, multidisciplinary Delphi panel, RISE Registry data review
- Modified Delphi process
- 3 consecutive Delphi sessions
- Multidisciplinary Delphi panel
- RISE Registry data review
Recommendations
As reported in the abstract
Quality constructs distilled
57
Quality measure statements
15
Statements meeting high consensus for importance and feasibility (2 treatment, 3 laboratory monitoring)
5
Highest-ranked statements recommended for measure specification: HCQ use; limiting GC use >7.5 mg/day to <6 months; kidney function and urine protein monitoring at least every 6 months
3
Original publication
Development of American College of Rheumatology Quality Measures for Systemic Lupus Erythematosus: A Modified Delphi Process With Rheumatology Informatics System for Effectiveness (RISE) Registry Data Review. Arthritis Care Res (Hoboken). Published 19 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →